We proposed some adjustments given that MDS patients and PPM1D mutations were not taken into account in the study by Lindsley et al. Based on the close interaction with TP53 in DNA damage response, we decided to consider PPM1D in the TP53 group more than “MDS-like” or “de novo/pan-AML”group in our Lindsley’s modified classifier, but larger series will help to clarify “prognosis role of PPM1D mutations” in the future. This evidence concerns the gene TP53 and myelodysplastic syndrome.